Gold prices bounce off 3-week lows; demand likely longer term
Investing.com -- Salarius Pharmaceuticals Inc (NASDAQ:SLRX) stock surged nearly 130% premarket after the company announced it received an extension from Nasdaq to regain compliance with listing requirements.
The biopharmaceutical company disclosed that the Nasdaq Hearings Panel has granted it additional time to meet the exchange’s listing standards. Salarius now has until mid-August 2025 to comply with the Equity Standard requirement and until late August 2025 to satisfy the Minimum Bid Price Requirement of $1.00 per share.
The company had previously received a delisting notice on April 23, 2025, for failing to maintain the minimum bid price requirement for 30 consecutive business days. Salarius was initially ineligible for the standard 180-day compliance period because it had conducted a reverse stock split within the prior year.
Additionally, Salarius had been notified on March 26, 2025, that it no longer complied with the Equity Standard based on its 2024 annual report. The company requested a hearing to appeal Nasdaq’s determination, which temporarily stayed any suspension or delisting action.
On June 11, 2025, the Hearings Panel granted Salarius an initial extension with specific compliance milestones. The panel subsequently provided additional extensions on July 11 and July 28, 2025, pushing the final deadlines to mid-August for the Equity Standard and late August for the Minimum Bid Price Requirement.
The extensions are contingent on Salarius achieving scheduled milestones and notifying Nasdaq of such achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.